Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

A 25-year-old man from Kerala died on the spot after a hit-and-run accident in the Whitefield Traffic Police limits on Monday night. The deceased has been identified as Abubakar Jayan, who was ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024, the share price was over DKK 1,000 per share. Now it is approaching DKK 400.The latest dip comes on Wednesday morning ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Ltd., a leader in premium interior design solutions, is thrilled to announce the launch of its new Experience Center in Whitefield, Bangalore. This new showroom reflects the company's ongoing ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.

Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources. --The Danish ...

HYDERABAD (Reuters) - Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly in the populous nation, two ...

Claim your 7-day free trial now. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD) outcomes trial. The study evaluated the once ...